Efficient, enantioselective synthesis of a β,β-disubstituted carboxylic acid by Ru-XylPhanePhos-catalyzed asymmetric hydrogenation

Tetrahedron Letters

Volumn 49, Issue 36, 2008, Pages 5328-5331

  Grasa, Gabriela A ^a   Zanotti Gerosa, Antonio ^b   Ghosh, Shyamali ^c   Teleha, Christopher A ^c   Kinney, William A ^c   Maryanoff, Bruce E ^c  

^a Johnson Matthey Catalysis and Chiral Technologies   (United States)

^b JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 QUINOLINYL DERIVATIVE; BIARYLPHOSPHINE; CARBOXYLIC ACID DERIVATIVE; PHOSPHINE DERIVATIVE; PROTEIN INHIBITOR; QUINOLINE DERIVATIVE; RUTHENIUM; VITRONECTIN RECEPTOR ANTAGONIST;

ARTICLE; CATALYST; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; ENANTIOSELECTIVITY; HYDROGENATION; SUBSTITUTION REACTION;

EID: 47749097898     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2008.06.068     Document Type: Article

References (40)

1. Dambacher J., Anness R., Pollock P., and Bergdahl M. Tetrahedron 60 (2004) 2097
2. Paquin J.-F., Stephenson C.R.J., Defieber C., and Carreira E.M. Org. Lett. 7 (2005) 3821
3. Appella D.H., Moritani Y., Shintani R., Ferreira E.M., and Buchwald S.L. J. Am. Chem. Soc. 121 (1999) 9473
4. Uemura T., Zhang X., Matsumura K., Sayo N., Kumobayashi H., Ohta T., Nozaki K., and Takaya H. J. Org. Chem. 61 (1996) 5510
5. Pai C.-C., Lin C.-W., Lin C.-C., Chen C.-C., Chan A.S.C., and Wong W.T. J. Am. Chem. Soc. 122 (2000) 11513
6. Tellers D.M., McWilliams J.C., Humphrey G., Journet M., DiMichele L., Hinksmon J., McKeown A.E., Rosner T., Sun Y., and Tillyer R.D. J. Am. Chem. Soc. 128 (2006) 17063 Rhodium catalyzed hydrogenation
7. Hoen R., Boogers J.A., Bernsmann H., Minnaard A.J., Meetsma A., Tiemersma-Wegman T.D., De Vries A.H.M., De Vries J.G., and Feringa B. Angew. Chem., Int. Ed. 44 (2005) 4209
8. Noyori R. Asymmetric Catalysis in Organic Synthesis (1994), John Wiley & Sons, New York Chapter 2
9. Tang X., and Zhang X. Chem. Rev. 103 (2003) 3029
10. Blaser H.U., Spindler M., and Studer M. Appl. Catal. A 221 (2001) 119
11. Blaser H.U., Malan C., Pugin B., Steiner H., Spindler F., and Studer M. Adv. Synth. Catal. A 345 (2003) 103
12. Sturm T., Weissensteiner W., and Spindler F. Adv. Synth. Catal. 345 (2003) 160
13. For Rh-catalyzed hydrogenation of unsaturated acids see. Boogers J.A.F., Felfer U., Kotthaus M., Lefort L., Steinbauer G., De Vries A.H.M., and De Vries J.G. Org. Proc. Res. Dev. 11 (2007) 585 and Refs. 4a,b
14. Döbler C., Kreuzfeld H.-J., Michalik M., and Krause H.W. Tetrahedron: Asymmetry 7 (1996) 117
15. Mousa S.A. Med. Res. Rev. 23 (2003) 190
16. Tucker G.C. Curr. Opin. Invest. Drugs 4 (2003) 722
17. Trikha M., Zhou Z., Nemeth J.A., Chen Q., Sharp C., Emmell E., Giles-Komar J., and Nakada M.T. Int. J. Cancer 110 (2004) 326
18. Hutchinson J.H., Halczenko W., Brashear K.M., Breslin M.J., Coleman P.J., Duong L.T., Fernandez-Metzler C., Gentile M.A., Fisher J.E., Hartman G.D., Huff J.R., Kimmel D.B., Leu C.-T., Meissner R.S., Merkle K., Nagy R., Pennypacker B., Perkins J.J., Prueksaritanont T., Rodan G.A., Varga S.L., Wesolowski G.A., Zartman A.E., Rodan S.B., and Duggan M.E. J. Med. Chem. 46 (2003) 4790
19. Coleman P.J., Brashear K.M., Askew B.C., Hutchinson J.H., McVean C.A., Duong L.T., Feuston B.P., Fernandez-Metzler C., Gentile M.A., Hartman G.D., Kimmel D.B., Leu C.-T., Lipfert L., Merkle K., Pennypacker B., Prueksaritanont T., Rodan G.A., Wesolowski G.A., Rodan S.B., and Duggan M.E. J. Med. Chem. 47 (2004) 4829-4837
20. Ghosh S., Santulli R.J., Kinney W.A., DeCorte B.L., Liu L., Lewis J.M., Proost J.C., Leo G.C., Masucci J., Hageman W.E., Thompson A.S., Chen I., Kawahama R., Tuman W.E., Galemmo Jr. R.A., Johnson D.A., Damiano B.P., and Maryanoff B.E. Bioorg. Med. Chem. Lett. 14 (2004) 5937
21. Santulli R.J., Kinney W.A., Ghosh S., DeCorte B.L., Liu L., Tuman R.W.A., Zhou Z., Huebert N., Bursell S.E., Clermont A.C., Grant M.B., Shaw L.C., Mousa S.A., Galemmo Jr. R.A., Johnson D.L., Maryanoff B.E., and Damiano B.P. J. Pharmacol. Exp. Ther. 234 (2008) 894
22. Synthesis of substrate 1 will be reported elsewhere.
23. n] led to full conversions and less than 25% ee's.
24. See Supplementary data for bisphosphine ligands employed in the initial catalyst testing.
25. Conversions and ee's throughout this study were determined by HPLC analysis using Chiracel AD-H column, hexane/i-PrOH = 80:20, after conversion to methyl ester.
26. Rossen K., Pye P.J., Reamer R.A., Tsou N.N., Volante R.P., and Reider P.J. J. Am. Chem. Soc. 119 (1997) 6207
27. Dominguez B., Zanotti-Gerosa A., and Hems W. Org. Lett. 6 (2004) 1927
28. Boulton L.T., Lennon I.C., and McCague R. Org. Biomol. Chem. 1 (2003) 1094
29. Pye P.J., Rossen K., Reamer R.A., Volante R.P., and Reider P.J. Tetrahedron Lett. 39 (1998) 4441
30. Burk M.J., Hems W.P., Herzberg D., Malan C., and Zanotti-Gerosa A. Org. Lett. 2 (2000) 4173
31. Rubina M., Rubin M., and Gevorgyan V. J. Am. Chem. Soc. 125 (2003) 7198
32. Solvent screening at S/C 500, 10 bar, 40 °C showed early on that MeOH was the best solvent for use in this system.
33. Kitamura M., Tokunaga M., Ohkuma T., and Noyori R. Tetrahedron Lett. 32 (1991) 4163
34. Kitamura M., Tokunaga M., Ohkuma T., and Noyori R. Org. Synth. 71 (1993) 1
35. Ashcroft C.P., Challenger S., Derrik A.M., Storey R., and Thomson N.M. Org. Proc. Res. Dev. 7 (2003) 362
36. Scrivanti A., Bovo S., Ciappa A., and Matteoli U. Tetrahedron Lett. 47 (2006) 9261
37. n] catalyst.
38. 3N as an additive, no conversion was observed in this system.
39. 2O in such systems led to low conversions and partial deprotection of the Boc group (3-15%).
40. Heiser B., Broger E.A., and Crameri Y. Tetrahedron: Asymmetry 2 (1991) 51